Worldwide, more than 55 million people suffer from dementia caused by Alzheimer's Disease (AD) and other conditions that destroy cells in the brain and nervous system. While there is no treatment to control or manage these neurodegenerative conditions, investigators have identified a new and promising drug to treat AD. The drug--and their approach by identifying a new target in the brain -- showed promising results in mouse models of AD.

In this special episode of Take on Tomorrow, PwC's Sarah von Fischer is joined by Carol Stubbings, PwC's Global Chief Commercial Officer, and Paul Griggs, PwC US Senior Partner. The trio discuss the findings of PwC's 28th Annual Global CEO Survey and unpack how leaders are tackling disruption.